A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

923

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: risedronate
DRUG: risedronate
DRUG: risedronate

Sponsor

Warner Chilcott